iTTP Survival Jumps From Near Zero to 93% With Modern Treatment Trio
A 2025 JAMA review breaks down how plasma exchange, rituximab, and caplacizumab transformed survival in this rare blood-clotting emergency.
Summary
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening condition where autoantibodies attack ADAMTS13, an enzyme that regulates blood clotting. Without it, massive clots form in small vessels, causing strokes, heart attacks, and organ failure. Affecting roughly 2–6 people per million annually, iTTP disproportionately strikes women, Black individuals, and adults. Modern treatment—combining therapeutic plasma exchange, corticosteroids, and rituximab—has raised 30-day survival from near zero to ~93%. Adding caplacizumab, a nanobody blocking platelet-vWF binding, accelerates platelet recovery and cuts short-term relapse risk by 29%, though it raises bleeding risk by 17%. Long-term remission monitoring via ADAMTS13 activity levels, with preemptive rituximab when levels drop below 20%, reduces clinical relapse risk by over 90%.
Detailed Summary
Immune thrombotic thrombocytopenic purpura (iTTP) is a medical emergency that physicians must recognize and treat rapidly. Caused by autoantibodies that cripple ADAMTS13—the enzyme responsible for cleaving von Willebrand factor—the disease allows ultra-large vWF multimers to accumulate, trapping platelets into microvasculature clots. The resulting ischemic organ damage manifests as strokes, seizures, myocardial infarction, and abdominal pain, with neurologic symptoms present in 39–80% of cases.
This 2025 JAMA review synthesizes current evidence on iTTP epidemiology, diagnosis, and management. Globally, incidence runs 2–6 cases per million per year, but risk is dramatically unequal: women are 3× more likely to be affected than men, Black individuals face a 7× higher incidence than non-Black individuals, and adults vastly outnumber children. These disparities point to genetic, immunologic, and possibly socioeconomic contributors.
Diagnosis relies on recognizing microangiopathic hemolytic anemia plus thrombocytopenia, supported by clinical scoring tools using platelet count and creatinine before ADAMTS13 results return. Treatment should not wait—empirical initiation of plasma exchange, corticosteroids, and rituximab is standard. This triple regimen achieves survival rates exceeding 90%, compared to near-universal fatality without treatment.
CaplaciZumab, a novel nanobody targeting the platelet-binding domain of vWF, is now used adjunctively. It shortens platelet count normalization and cuts 30-day recurrence risk by 29 percentage points, but increases clinically meaningful bleeding by 17 percentage points—a trade-off clinicians must weigh carefully.
Perhaps most actionable for long-term management: regular ADAMTS13 monitoring in remission catches subclinical relapse risk early. Preemptive rituximab for patients with ADAMTS13 activity below 20% slashes clinical relapse odds by 91% (OR 0.09). For a disease with a 16% relapse rate post-remission, this surveillance strategy is a meaningful advance.
Key Findings
- Triple therapy (plasma exchange, corticosteroids, rituximab) raises iTTP 30-day survival from near zero to ~93%.
- Black individuals face 7× higher iTTP incidence than non-Black individuals; women face 3× higher risk than men.
- Caplacizumab reduces early relapse risk by 29% but increases bleeding risk by 17% versus placebo.
- ADAMTS13 activity below 20% in remission signals relapse risk; preemptive rituximab cuts relapse odds by 91%.
- Neurologic symptoms appear in 39–80% of iTTP patients, making early recognition critical for stroke prevention.
Methodology
This is a narrative review published in JAMA in 2025, synthesizing existing clinical evidence, epidemiological data, and trial results. It draws on randomized controlled trial data for caplacizumab and observational cohort data for epidemiologic estimates. No primary data collection was performed.
Study Limitations
As a review, this paper synthesizes existing literature and is subject to the biases of included studies. Epidemiologic incidence ratios may reflect healthcare access disparities rather than true biological differences. Caplacizumab bleeding risk data are from controlled trials and may differ in real-world practice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.